bevacizumab

Shares of Novocure Ltd (NASDAQ: NVCR) surged higher on Monday by more than 10 percent. Novocure announced new Phase 3 data, in which patients who received the company's Optune in combination with bevacizumab at first recurrence lived "significantly longer" than those who just received bevacizumab...